KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) EBIT (2018 - 2025)

Vir Biotechnology (VIR) has disclosed EBIT for 8 consecutive years, with -$47.9 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 59.09% to -$47.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$479.3 million through Dec 2025, up 18.37% year-over-year, with the annual reading at -$479.3 million for FY2025, 18.37% up from the prior year.
  • EBIT hit -$47.9 million in Q4 2025 for Vir Biotechnology, up from -$173.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $1.0 billion in Q1 2022 to a low of -$231.3 million in Q3 2024.
  • Historically, EBIT has averaged -$24.8 million across 5 years, with a median of -$139.3 million in 2023.
  • Biggest YoY gain for EBIT was 739.1% in 2022; the steepest drop was 469.11% in 2022.
  • Year by year, EBIT stood at $571.8 million in 2021, then crashed by 126.32% to -$150.5 million in 2022, then increased by 7.63% to -$139.0 million in 2023, then rose by 15.73% to -$117.2 million in 2024, then surged by 59.09% to -$47.9 million in 2025.
  • Business Quant data shows EBIT for VIR at -$47.9 million in Q4 2025, -$173.4 million in Q3 2025, and -$118.4 million in Q2 2025.